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Abstract Human ICAM- expression is up-regulated by IFN-r and TNF-a and synergistically increased by a combination of both. Transient 
expression of ICAM-l/luciferase constructs led to definition of the regulatory regions mediating the cytokine response and showed that both are 
necessary for synergism. Immunochemical electromobility shift assays identified the TNF-o-dependent complexes that bound to the NF-rcB like 
sequence at -187 as p65/p50 and p65/c-Rel. The interferon responsive region at -75 was bound by a Statla (p91) containing complex that was 
activated by both IFN-y and IFN-a. Although both regions were required for synergism, no additional or enhanced binding complexes were observed. 
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1. hltroduction 
The glycoprotein intercellular adhesion molecule 1 (ICAM- 
1) serves as a counter-receptor for leukocyte 82 integrins and 
for the T cell mucin CD43 [l-4]. The interaction between 
ICAM- and its ligands is an important step in the development 
of the inflammatory response strengthening effector-target in- 
teractions and mediating leukocyte migration into the tissues 
[5,6]. While constitutive expression of ICAM- is restricted to 
a few cell types [ 1,7-lo], ICAM- can be induced on essentially 
any cell type by IFN-y and TNF-a [5,8,1 l-151. Cytokines are 
often expressed in combination in vivo [16], and IFN-)I plus 
TNF-a can act synergistically to enhance ICAM- expression 
[5,13,14], as has been seen with MHC class I [17] and IL-8 [18]. 
We have determined the regions of the ICAM- promoter that 
are responsive to IFN-y and TNF-a, and characterised the 
nuclear complexes binding to them. Following exposure to 
TNF-a the NF-KB-like responsive region RRBE (Rel-related 
protein binding region) is bound by two complexes, ~501~65 
and a p65/c-Rel heterodimer. Stimulation with either IFN-r or 
IFN-a led to binding to the interferon-responsive element of a 
protein complex shown to contain Statla (p91). Protein bind- 
ing to both regions was required for the synergistic effect of 
TNF-a plus IFN-*/, however, additional or enhanced protein 
complexes were not observed. 
2. Material aad methods 
2.1. Transient transfection and cyokine stimulation 
Human melanoma cell line Mel JuSo was cultured as described [19]. 
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Abbreviations: EMSA, electromobility shift assay; GAF, y-activated 
factor; GAS, y-activated sequence; ICAM-1, intercellular adhesion 
molecule-l; IFN, interferon; IRE, interferon-responsive lement; 
ISGF, interferon a-stimulated gene factor; RRBE, Rel-related protein 
binding element; TNF, tumor necrosis factor; TNF-R, TNF-a receptor. 
0014-5793/94/$7.00 0 1994 Federation f European Biochemical Societies. 
SSDZ 0014-5793(94)01130-3 
Transient transfections were performed using the Transferrinfection 
system (Serva, Heidelberg, Germany). The constructs, transfection and 
luciferase assays have been described [12,19]. Six hours following trans- 
fection, the cells were washed with prewarmed medium and incubated 
for a further 24 h in fresh medium with or without cytokines. Re- 
combinant human IFN-y and IFN-a was obtained from Biogen, 
Cambridge, MA. Recombinant human TNF-a (7.4 x lo6 U/mg) was 
kindly provided by Dr. T. Subkowski, BASF, Ludwigshafen, Germany. 
Cells were treated with 100 U/ml IFN-y, 1,000 U/ml IFN-cc and 200 
U/ml TNF-a where indicated. 
2.2. Indirect immunofuorescence, flow cytometry and Northern blot 
analysis 
Expression of ICAM- on the cell surface was determined by indirect 
immunfluorescence using the anti ICAM- mab P3.58BA-11 [20] or an 
isotype control upcl0 (Sigma, St. Louis, MO). Total RNA was pre- 
pared using a modification of the caesium trifluoracetate method 
(CsTFA; Pharmacia, Freiburg, Germany). The sequence of the 
GAPDH-specific oligonucleotide was 5’ CCCTGGTGACCAGGCG- 
GCCAATACGGCCAATCCGTTGACTCCGACTI-TCCAC 3’ [21]. 
For further details see the legend to Fig. 1B. 
2.3. TNF receptor binding assay 
TNF-a was labelled with rzSIodine by the chloramine-T method [22]. 
Specific radioactivity was 20 PCiipg for [‘ZSI]TNF-a, and the recovery 
of biological activity was 74%. Mel JuSo cells were cultured in 24-well 
plates (Costar, Femwald, Germany) with or without IFN-)I for 24 h 
to subconfluent state (about 7 x lo5 cells/well). Specific binding of the 
radiolabelled TNF-a applied to the cells for 2 h at 4’C at a concen- 
tration of 0.5 nM, in the presence or absence of antibodies against 
TNF-R p75 and ~55, was determined as described ([23] and references 
therein). 
2.4. Nuclear extracts and electromobility shift assays (EMSA) 
Nuclear extracts were prepared as described [24]. Binding reactions 
were performed in a 20 ~1 reaction volume containing 20 mM HEPES, 
1 mM MgC&, 50 mM KCl, 12% glycerol, 0.1 mM EDTA, 0.5 mM 
PMSF (phenyhnethylsufonic a id), 0.5 mM DTT (dithiothreitol), 5 pg 
of nuclear protein and 1 pg poly[d(A-T)] (Boehringer, Mannheim, Ger- 
many) as unspecific ompetitor. After 10 min on ice 10 fmol 3zP-labelled 
oligonucleotide and, where indicated, unlabelled competitor oligonu- 
cleotide in excess were added and incubation was continued for 1 h 
further. Samples were run on a 4% polyacrylamide gel (38 : 1) in 0.25 x 
TBE (prerun for 1 h) at 150 V for 2.5 h. The dried gels were exposed 
for autoradiography overnight. 
All rights reserved. 
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2.5. Oligonucleotides 
Oligonucleotides were annealed and labelled with [a-‘*P]dATP 
(Amersham, Braunschweig, Germany). Oligonucleotides with a 5’ over- 
hang were labelled with Klenow polymerase (Boehringer, Mannheim, 
Germany), others with terminal deoxytransferase (G&co-BRL, 
Gaithersburg, MD). The sequences of the oligonucleotides used are as 
follows (5’+3’; lower case letters indicate added cloning sites; the 
complementary sequence is not shown): 
ICAM/NF-KB, cgggatccClTGGAAAl-KCGGAGC (-189 to - 173) 
ICAM/IRE, cgggatccGTITCCGG&AAAGCAGCA (-77 to -60) 
ICAM/SPl , cgggatccAGCACCGCCCCTTGG (-63 to -49) 
ICAM/AP2, cgggatccCTTGGCCCCCAGGTG (-53 to -39) 
HIWNF-rcB, AGCTTCAGAGGGGACTTTCCGAGAGG [25] 
GAS, catgAGTTTCATAlTACTCTAAATC [26] 
IREGC, CgggatccGAAAGCGAAAGCGAAAGCGAAAGC [27]. 
2.6. Immunochemical identification of nuclear factors (antibody 
EMSA) 
Nuclear extracts and oligonucleotides were incubated on ice for 15 
min. antibodies 12 ul. 100 u&l) were added and the mixture incubated 
for a further 1 h bd i&. Thk antibodies used (Santa Cruz Biotech., Santa 
Cruz, CA) were a monoclonal antibody directed against ISGF-3 ~91, 
rabbit polyclonal anti-p65, anti-c-Rel and anti-p52 antiserum, an 
isotype control monoclonal anti-TNF-R p75 [23] and normal rabbit 
serum. Antiserum directed to p50 (Santa Cruz Biotech.) was used as an 
agarose-conjugate. In this &se, nuclear extracts were incubated for 
1 h on ice with 20 ul QO ua IgGIul anarose) anti-u50 or normal rabbit 
IgG-agarose, cent6fuiedj &itd su&mat&t used in the binding reac- 
tion. 
3.Results 
The melanoma cell line Mel JuSo constitutively expresses 
ICAM- on its cell surface, as determined by indirect im- 
munofluorescence and flow cytometry. Treatment for 24 h with 
either IFN-y or TNF-& increased this expression, and a combi- 
nation of both cytokines gave rise to a synergistic increase in 
ICAM- expression (Fig. 1A) that was associated with in- 
creased steady-state mRNA levels. Induction for 4 h with the 
cytokines either alone or in combination led to an increase in 
ICAM- mRNA as compared to the mRNA of the GAPDH 
gene (Fig. 1B). Densitometric analysis and comparison of 
ICAM-I mRNA with that of GAPDH revealed an increase of 
ICAM- mRNA of approximately lo-fold with IFN-~,20-fold 
with TNF-a and 80-fold with a combination of both. 
In order to determine the regions responsible for the syner- 
gistic activation of ICAM-1, its 5’ upstream region from - 1352 
to +l (the downstream transcription start site was set to + 1 [28]) 
was placed in front of the promoterless luciferase reporter gene 
construct pXP-2 [29]. Mel JuSo cells were transiently trans- 
fected with plasmids containing the 5’ end and internal dele- 
tions for 6 h, washed once and then exposed to IFN-y, TNF-a 
or both for 24 h. The luciferase activity of the induced cells was 
compared to that of the untreated cells and the results are 
shown in Fig. 2 as fold induction for each of the plasmids used. 
The promoterless construct pXP-2 was used as a negative con- 
trol and showed no inducibility by either cytokine. All 
constructs containing between 1352 and 339 bp of the 
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Fig. 1. TNF-a plus IFN-y synergistically increases ICAM- 1 expression 
in Mel JuSo cells. (A) FACS profiles (relative fluorescence vs. cell 
number) for Mel JuSo cells stained with monoclonal antibody 
P3.58BA-11 directed against ICAM-1. The cells were either left un- 
treated or were treated with indicated cytokines for 24 h. The fluores- 
cence of isotype control antibody upcl0 was subtracted from the 
ICAM- graphs. (B) Northern blot of ICAM-1. 20 pg total Mel JuSo 
RNA treated as indicated (U, uninduced, I, IFN-7; T, TNFa; IT, both 
cytokines) for 4 h were electrophoresed, blotted and hybridised with an 
ICAM- cDNA 690 bp PstI fragment followed by an oligonucleotide 
specific for the GAPDH gene. The size (kb) of the three observed 
ICAM- mRNAs are indicated. 
222 A. Jahnke, J.R JohnsonlFEBS Letters 354 (1994) 220-226 
fold induction 
. . - 3 
4- , / PIG-1 352 







-. . _, . -e PlC-277AAP2 
qEJ pxp-2 
Fig. 2. The NF-rcB and the IRE sites are necessary for a synergistic response to TNF-a and IFN-r in Mel JuSo. The right side indicates the fold 
induction of the transiently transfected constructs under the influence of TNF-a (T, hatched bars), IFN-r (I, striped bars) and IFN-y plus TNF-a 
(IT, open bars) for 24 h. The luciferase activity of the uninduced cells (U, filled bars) was set at 1. The left side shows a scheme of the ICAM- 5 
region cloned in front of a luciferase gene (LUC). TATAl and -2 represent he downstream and upstream TATA box of the ICAM- promoter, 
respectively. IRE, interferon responsive lement; NF-kB, NF-KB binding site; AP2 and SPl, binding sites for transcription factors AP-2 and Spl . 
A, AccI; H, HindIII; S, SmuI; p, PstI; N, NcoI. 
TNF-a (hatched bars), 1Cfold induction with IFN-y (striped 
bars) and a 55-fold induction with both cytokines (open bars). 
Deletion to position -277 reduced overall inducibility (perhaps 
a reflection of the higher constitutive expression of these con- 
structs [ 191). but still showed synergistic induction with IFN-y 
plus TNF-a. The shortest construct, pIC-34, containing only 
the downstream TATA box, showed no inducibility with either 
cytokine. Deletion of the region between -277 and -174 abol- 
ished the TNF-a inducibility as well as the synergistic effect but 
did not affect IFN-y inducibility. An internal deletion in pIC- 
277, which removed the SmuI fragment between -227 and 
-136, also abolished the TNF-a response. Thus the element 
mainly responsible for TNF-a induction lies between position 
-227 and -174. Interestingly the inducibility of pIC-277dSma 
by IFN-y was higher than that of pIC-174 or pIC-277, although 
the constitutive level of pIC277dSma was identical to that of 
pIC-277. Sequence comparison of the region between -227 and 
-174 revealed good homology to a NF-KB consensus motif at 
bp -187 to -178. 
An internal deletion in pIC-277 between position -107 and 
-34 revealed that this region is responsible for interferon induc- 
ibility. Construct pIC-277dAP2 showed no inducibility after 
treatment with IFN-r, but still was induced with TNF-a. The 
combination of IFN-y plus TNF-a had no additional effect on 
the induction. Plasmid pIC-277dAP2 (that showed low consti- 
tutive expression) led to a much higher inducibility with TNF-a 
than did pIC-277, the construct without internal deletion. Se- 
quence analysis of the region from - 107 to -34 revealed homol- 
ogy between -75 and -66 and published sequences of elements 
responsible for the IFN-y response (called here IRE for inter- 
feron-responsive lement). 
In order to exclude the possibility that the synergism ob- 
served could be due to an increase in TNF-a receptor expres- 
sion under the influence of IFN-y we analysed the binding 
of radioactively labelled TNF-a to Mel JuSo cells treated for 
24 h either with IFN-y (100 U/ml) or only with medium as a 
control. A less than 10% increase in binding of TNF-a was 
observed after IFN-y treatment, indicating that the increase in 
the TNF receptor is not responsible for the synergism observed 
in ICAM- expression (data not shown). In addition, exposure 
of the cells to TNF-a alone followed by washing and exposure 
to IFN-y 3 h later still led to synergistic induction of reporter 
gene constructs, confuming that synergism does not depend on 
an increase in TNF-R. 
Electromobility shift assays (EMSAs) were performed using 
the putative ICAM- NF-rcB motif and nuclear extracts ob- 
tained from Mel JuSo cells treated for 15 rain with IFN-y, 
TNF-a, both cytokines or medium alone (Fig. 3A). Exposure 
of the cells to TNF-a either alone (lane 4) or in combination 
with IFN-y (lane 5) led to the appearance of one new band 
(lower complex, LC) and a dramatic increase in the amount of 
a second complex (upper complex, UC). Competition with un- 
labelled oligonucleotides uggested that these two complexes 
reflect the binding of NF-KB. Both bands were inhibited by the 
HIWNF-XB binding sequence (lanes P-11) as well as by the 
unlabelled putative ICAM- NF-KB binding sequence (lanes 
6-8) but were not influenced by the presence of ICAM- Spl 
(lane 12) AP-2 or binding sites (lane 13). A third weak band 
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Fig. 3. EMSAs with oligonncleotides containing the ICAM- NF-nB or IRE sites and immunochemical identification of the cytokine specific 
complexes. (A) ICAMDJF-KB oligonucleotide with extracts of cells left untreated or treated with IFN-I, TNF-a or both cytokines for 15 min (lanes 
2-5). Unlabelled competitor ICAIWNF-rcB (lanes 68) and HIVINF-rcB (lane !%ll) was added in increasing concentrations (lo-, 50-, 250-fold excess), 
while ICAMlSPl, ICAMlAP2 and IREGC were added at 250-fold excess (lanes 12,13,20). Antibodies (lanes 14-19) were used as described in section 
2. UC and LC are the upper and lower complexes, respectively. (B) Oligonucleotides ICAMlIRE (lanes 1-14) and GAS (lanes 15,16) generate an 
IFN-y induction specific complex (SC). Competition of ICAIWIRE with itself (lanes 6-g) or GAS (lanes 9-11) with increasing excess (lo-, 50-, 
250-fold). IREGC 250-fold (lane 12). Antibody p91 and isotype control (lanes 13,14) used as described in section 2. 
migrating slightly faster than UC was sometimes observed with 
extracts of both interferon-induced and uninduced cells (lanes 
2 and 3). While competition with unlabelled HIV/NF-XB 
oligonucleotide readily inhibited the TNF-a-specific bands (UC 
and LC), this diffuse band was not affected. Thus this band 
seems to be cytokine independent and NF-fcB unspecific. Two 
fast migrating bands were observed with all extracts and were 
independent of cytokine treatment. These complexes appar- 
ently reflect binding to the filled-in BarnHI cloning sites present 
in the ICAM-l/NF-KB oligonucleotide, as they are inhibited by 
an unrelated filled-in competitor oligonucleotide (IREGC, lane 
20). 
Specific antibodies were used to determine the composition 
of the observed complexes. Exposure of the nuclear extracts of 
TNF-a-treated cells to insolubule anti-p50 reduced the inten- 
sity of LC without affecting the upper band (lane 14). Control 
rabbit IgG had no effect on either band (lane 15). The addition 
of anti-p65 supershifted both LC and UC (lane 17), indicating 
that both complexes contain ~65. An antibody directed against 
c-Rel supershifted only UC (lane 18). Rabbit IgG (lane 19) and 
an antibody against p52 (lane 16) had no effect on either com- 
plex. These results indicate that LC consists of a p65/p50 (NF- 
fcB) heterodimer while UC consists of a p65/c-Rel heterodimer. 
Following exposure to IFN-y either alone or in combination 
with TNF-a, a single new specific complex (SC) was observed 
(Fig. 3B, lanes 3 and 5). This band was not detected with cell 
extracts of uninduced or TNF-a-treated cells (lanes 2 and 4) 
and was inhibited by unlabelled ICAM/IRE (lanes 6-8) and to 
a lesser extent by unlabelled GAS oligonucleotide (lanes 9-l 1) 
containing the GBP gene consensus binding site for the GAF 
[30]. A related oligonucleotide, IREGC, containing 4 repeats 
of the GAAAGC motif shown to be responsible for IEN-aY~ 
and virus inducibility [31], did not compete with this complex 
(lane 12). Additional bands were observed with nuclear extracts 
of Mel JuSo cells independently of cytokine exposure, indicat- 
ing that these complexes are not involved in the IFN-y re- 
sponse, although the fastest migrating band could be outcom- 
peted with unlabelled and not tilled-in GAS and IREGC 
oligonucleotides (lanes 9-12). 
Treatment with a monoclonal antibody raised against the 
ISGF-3 p91 protein (= Statla = Stat91) depleted SC (lane 14), 
indicating that this complex contains p91 or an antigenically 
related protein. An isotype control antibody against p75 TNF 
receptor had no iniluence on the observed complexes (lane 13). 
EMSAs performed with labelled GAS oligonucleotide 
(shown to bind p91; GAF[26]) revealed, in extracts of IFN-y- 
induced cells, the formation of a band migrating similarly to the 
p91-containing complex (lanes 15 andl6), suggesting identity 
with both complexes. 
ICAM- expression in Mel JuSo cells can also be up-regu- 
lated by IFN-a. We therefore examined whether IFN-a (1000 
U/ml, 15 min incubation) could also induce a protein binding 
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4. Discussion ICAM/IRE GAS 




Fig. 4. Induction with IFN-a led to a specific omplex (SC) identical 
to that observed after IFN-y treatment. Mel JuSo cells were left un- 
treated or were induced with.IFN-y (lanes 1,2 and 7,8) or IFN-a (lanes 
3-6,9) for 15 min. Competitor GAS and IREGC were added at 250-fold 
excess (lanes 4,5), anti p91 (lane 6) was used as described in section 2. 
to the ICAMlIRE and GAS oligonucleotides. Nuclear extracts 
of induced Mel JuSo cells incubated with either oligonucleotide 
led to a complex with identical migration characteristics to that 
observed after treatment with IFN-y (Fig. 4, lanes 2,3 and 8,9). 
Competition analysis showed that the GAS oligonucleotide was 
also a potent competitor of the IFN-a-induced complex (lane 
4), while IREGC did not compete even at a 250-fold excess 
(lane 5). Using the anti-p91 antibody the bound protein was 
identified as a p91-containing complex (lane 6). 
Nuclear extracts prepared from Mel JuSo cells exposed to 
IFN-y and TNF-a formed the same complexes with ICAM/ 
NF-XB and ICAM/IRE oligonucleotides and with similar in- 
tensities as observed with TNF-a and IFN-y alone (Fig. 3A, 
lanes 4 vs. 5; Fig. 3B, lanes 3 vs. 5). To rule out oligonucleotide 
binding-induced changes in protein conformation, 10 fmol of 
unlabelled ICAM/NF+B was added to the ICAM/IRE binding 
experiments and unlabelled ICAM/IRE to the ICAMRVF-KB 
binding experiments. No additional or enhanced bands were 
observed in the nuclear extracts from cells exposed to both 
IFN-y and TNF-a (data not shown). In order to exclude the 
possibility that the observed synergistic induction of ICAM- 
was mediated by NF-XB and the AP-2 or Spl binding site close 
to the IRE element, oligonucleotides ICAM/AP2 and ICAM/ 
SPl were tested for interaction with nuclear extract of cells 
treated with either cytokine alone or a combination of inter- 
feron and TNF. Neither sequence revealed a cytokine-specific 
or enhanced complex, indicating that these regions play no role 
in TNF-a- or IFN-y-mediated ICAM- 1 induction (unpublished 
observation). 
Exposure of a variety of cell types to IFN-y or TNF-a results 
in increased surface ICAM- expression which is synergistic in 
the presence of both cytokines [5,13,14]. Surface expression 
correlates with steady-state mRNA levels, indicating that the 
regulation of ICAM- expression by cytokines occurs at the 
transcriptional evel [ 11,13,15]. Using transient transfection of 
reporter gene constructs, containing 5’ end and internal dele- 
tions of the region upstream of the ICAM- gene, the regions 
responsible for these responses have been identified, and using 
EMSAs the protein complexes binding to these regions have 
been characterised. 
The position of the TNF-a responsive element in Mel JuSo 
(bp -227 to -174) is identical to that observed in other cells 
[12,31], indicating a general TNF-a induction pathway con- 
cerning ICAM-1. The TNF-a-responsive region contains an 
NF-lcB-like motif and, as has recently been reported in TNF- 
a-treated U937 cells, 2 specifically binding complexes (LC, UC; 
Fig. 3A) were observed in Mel JuSo cells. Cells that were 
cytokine treated for 3 h instead of 15 min generated the same 
bands, although they were weaker, indicating a low stability of 
the induced complexes (data not shown). 
Antibodies directed against various Rel-related proteins 
were used to character& the proteins binding to this region, 
and identified the lower complex as p65/p50 (NF-KB protein) 
and the upper one as p65/c-Rel heterodimer. An element in the 
human urokinase gene (uPA) binding both ~651~50 and p65/c- 
Rel, termed RRBE (Rel-related protein-binding element) [32], 
shows homology to the ICAM- sequence (uPA, GGGAAAG- 
TAC; ICAM- 1, TGGAAATTCC). The p65/c-Rel complex has 
recently been shown to be a strong activator of transcriptional 
activity [33], and the results reported here indicate that this 
complex is involved in the up-regulation of ICAM- by TNF-a. 
The interferon-responsive region in Mel JuSo was identified 
between position - 107 and -34. This correlates with results of 
Look et al. [l l] and Wawryk et al. [34] but stands in contrast 
to Voraberger et al. [31] who observed an interferon-response 
element upstream of position -1352. Using a longer construct, 
pIC-5800, we could not detect any further interferon-respon- 
sive region in Mel JuSo, suggesting that the ICAM- response 
to IFN-y may be regulated differently in various cells. 
The region mediating the IFN-y induction in Mel JuSo cells 
contains a palindromic sequence, TTICCGGGAAA, at bp 
-76 to -66, that is homologous to GAS sequences of other 
IFN-y-responsive genes [35]. This sequence bound an IFN-y 
induction specific nuclear complex (Fig. 3B, lane 3 vs. 2,4), 
confirming results of Look et al. [ 1 l] who showed that the same 
sequence mediates the IFN-y response in epithelial cells. Using 
a monoclonal antibody that is not cross-reactive with p84 
we could show that the specific band contains p91 
(= Statla = Stat91 [36]), probably binding as a homodimer 
(GAF) [37]. 
The IFN-y-induced complex observed in Mel JuSo cells 
could be inhibited by unlabelled GAS oligonucleotide (50-fold 
excess; Fig. 3B, lane 10) and was also detected when radiola- 
belled GAS was used for binding (lane 16). Using a 20-fold 
excess of unlabelled GAS oligonucleotide Look et al. could 
not inhibit this complex, although a 20-fold excess of the gam- 
maresponse region (GRR) of the FcyRI gene was a potent 
competitor [ll]. Sequence. comparison between the binding 
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regions of ICAM/IRE (TTCCGGGAA), FcyRIIGRR 
(TTCCCAGAA [38]) and GBPIGAS (TTACTCTAA [26]) sug- 
gest that the GRR of the FcyRI gene could be a better compet- 
itor of the ICAM-I binding complex. Furthermore other 
groups have shown cross-competition of the FcyRI GRR and 
the related ICSBP elements with 50- or loo-fold excess of GAS 
oligonucleotides [38,39]. These results indicate that ICAM/ 
IRE, GAS and GRR are able to bind the same IFN-y-induced 
complex(es), albeit with different binding affinities. A 250-fold 
excess of an oligonucleotide containing a 4-fold repeat of 
GAAAGC (one half side to the ICAM/IRE palindrome) did 
not compete for the specific complex, indicating that this pro- 
tein needs the full palindrome for binding (lane 12 IREGC). 
Since MacDonald [27] could show that this site conferred IFN- 
a, y and virus inducibility, it seems possible that this oligonucle- 
otide actually binds a protein not identical with ~91. Cells 
treated for 3 h with IFN-y showed the same specific interferon 
band with nearly the same strength. 
Treatment of cells with IFN-a led to the same band with 
oligonucleotides ICAMlIRE and GAS as was observed with 
IFN-)I (Fig. 4, lanes 2,3 and 8,9). This band was also depleted 
by unlabelled GAS oligonucleotide and was reduced by anti- 
~91. Thus IFN-a and IFN-y seem to induce, at least in this in 
vitro assay, the same binding protein in Mel JuSo. Similar 
observations were made by Kanno et al. [39] with the murine 
ICSBP gene. 
Exposure of transfected cells to both TNF-a and IFN-*/ led 
to a synergistic increase in reporter gene expression (Fig. 2; 
55-fold vs. 6- and 1Cfold). Analysis of deletion constructs re- 
vealed that both elements, the NF-KB/RRBE site as well as the 
IRE/GAS site, are involved in this synergism. Deletion of either 
cytokine-responsive site led to a loss of synergistic induction. 
EMSAs with other putative transcription factor binding sites 
in the responsive regions excluded them as responsive sites, 
contirming the importance of the IRE/GAS and the NF-xBI 
RRBE sites. 
IFN-)I and TNF-ol lead to synergistic effects on the expres- 
sion of a number of different genes [ 17,181. Increase in TNF-a 
receptor expression by IFN-)I has only been observed in certain 
cases and seems to be cell-type dependent [18,4043]. Exposure 
to IFN-)I had no effect on the TNF-R expression in Mel JuSo, 
suggesting that synergistic induction by TNF-a and IFN-y is 
mediated by an element downstream of the cytokine receptors. 
In other cases, the synergistic induction of transcription is asso- 
ciated with augmented nuclear complex bands [18] or with the 
appearance of a new band due to adjacent binding of two 
transcription factors on one oligonucleotide [17]. Using puri- 
fied proteins, a physical interaction of transcription factors has 
been shown, for example between NF-nB and members of the 
C/EBP family and with Spl [44-46], a phenomenon that could 
be responsible for cytokine-mediated synergism in gene expres- 
sion. 
Although we detected cytokine-specific omplexes with ol- 
igonucleotides, no new bands or changes in band intensity were 
observed in the nuclear extracts of Mel JuSo cells treated with 
a combination of IFN-y and TNF-ol. This suggests either that 
the protein-protein interaction is too weak to be detectable in 
the absence of purified proteins or that the DNA structure may 
play a role in synergism. The use of a 126 bp PCR product from 
position -189 to -63, comprising both the NF-KB/RRBE and 
IRE/GAS sites, was unable to resolve this question since the 
225 
large number of proteins binding to this fragment obscured any 
differences between cytokine-treated and untreated cells. Thus 
although we identified and characterised the elements necessary 
for the synergistic increase of ICAM- expression induced by 
TNF-d and IFN-y and examined some possible ways of inter- 
action, further experiments (perhaps with purified protein) are 
still necessary to determine the mechanism of synergism. 
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